New market study, "Market Opportunities for Supergenerics", has been published

Jan. 19, 2011 - PRLog -- The negative economic climate has meant that governments and payors alike are looking at reducing the prices of drugs as one way to contain costs. This has particularly affected areas where there is strong competition as with commodity generics. This report assesses the potential of new supergenerics in the setting of specific therapeutic classes. The report identifies the drivers and resistors for developing supergenerics in different countries and regions, and evaluates regulatory issues that hamper or encourage the development of supergenerics. It also evaluates the different company types that are involved in the supergeneric sector.

Scope of this research
Assess the competitive environment for supergenerics.
Evaluate the pros and cons in adopting a supergeneric strategy and see how your company might take steps to improve its skills and know-how.
Identify strategies and therapy areas most likely to be successful in the supergenerics area.
Understand the situation in terms of competing technologies in the development of supergenerics and which ones are more advanced in development.
Identify technologies which may be useful in developing supergenerics.

Research and analysis highlights

The report identifies that there is still considerable scope for gaining price premiums for supergenerics in most areas studied. Although price premiums are obtainable in free price setting markets like the US the situation in the EU is complicated and reimbursement levels may pose another hurdle for SG producers in the diverse EU market place.

SG producers have been forced to focus on areas of unmet medical need and high sales potential markets such as the CNS area, as innovative companies have already patented widely and developed many line extensions in more obvious and easy to formulate areas such as cardiovascular, with single isomers, combinations, extended release, and prodrugs.

There are considerable opportunities for licensing products for wider markets as often SG producers concentrate on just one market and require licensing partners to reach other geographic areas and will usually have no access to emerging markets which offer potential for SG sales.

Key reasons to purchase this research
Where are the most successful supergenerics markets?
What effect are government policies having on the supergenerics sector?
What technologies are offering important advances in certain therapy areas?
Are supergenerics patents more susceptible to generic challenges than NCE patents?
Which companies have been successful in developing supergenerics and will this success continue?


For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/109731_market_opportunities_fo...


Partial Table of Contents:

TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2003-15 6
Financial performance, 2003-15 7
Novartis: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 19
Chapter 3 Quarterly update 28
Latest quarterly sales 28
Latest quarterly financial analysis 29
Latest comment 31
Latest prescription pharma product news 40
Latest corporate news 47
Chapter 4 Company introduction 51
Key findings 51
Background 52
Key corporate developments 52
M&A history 52
Chapter 5 Company sales 57
Key findings 57
Prescription pharmaceutical sales and growth rate analysis, 2003-15 58
Product analysis 60
Therapy area analysis 70
Geographic analysis 73
Launch/core/expiry analysis 75
Molecule type analysis 82
Externalization analysis 85
Chapter 6 Company financials 88
Key findings 88
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09 89
perating costs and profit analysis 90
Chapter 7 Key products 95
verview 95
Chapter 8 Appendix 125
References 125
Abbreviations 125
Exchange rates 126
About Datamonitor 127
Datamonitor consulting 127
Disclaimer 129

TABLE OF TABLES
Table 1: Novartis - PharmaVitae forecasts at a glance 8
Table 2: Novartis quarterly sales ($m), Q309-Q310 28
Table 3: Novartis quarterly financials ($m), Q309-Q310 29
Table 4: Novartis product portfolio overview ($m), 2003-09 62
Table 5: Novartis product portfolio overview ($m), 2009-15 66
Table 6: Novartis prescription pharmaceutical sales by therapy area ($m), 2009-15 72
Table 7: Novartis prescription pharmaceutical sales by geographic region ($m), 2009-15 74
Table 8: Novartis launch portfolio overview ($m), 2009-15 76
Table 9: Novartis core portfolio overview ($m), 2009-15 77
Table 10: Novartis expiry portfolio overview ($m), 2009-15 78
Table 11: Novartis (Sandoz) generics portfolio overview ($m), 2009-15 79
Table 12: Novartis prescription pharmaceutical sales by molecule type ($m), 2009-15 84
Table 13: Novartis prescription pharmaceutical sales by source ($m), 2009-15 87
Table 14: Total Novartis sales by business unit ($m), 2003-09 89
Table 15: Novartis operating revenue/cost analysis ($m), 2003-09 91
Table 16: Novartis operating cost ratio analysis (% of total revenues), 2003-09 92
Table 17: Novartis operating cost ratio analysis (% of total revenues), 2009-15 93
Table 18: Novartis operating revenue/cost analysis ($m), 2009-15 94
Table 19: Novartis Key products overview 95
Table 20: Glivec/Gleevec: overview 97
Table 21: Glivec/Gleevec: sales forecast ($m), 2009-15 98
Table 22: Gilenia: overview 101
Table 23: Gilenia: sales forecast ($m), 2009-15 102
Table 24: QMF149: overview 104
Table 25: QMF149: sales forecast ($m), 2009-15 105
Table 26: QVA149: overview 107
Table 27: QVA149: sales forecast ($m), 2009-15 108
Table 28: Tasigna: overview 110
Table 29: Tasigna: sales forecast ($m), 2009-15 111

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1097...

About Business Insights

Business Insights appreciate the importance of accurate, up-to-date incisive market and company analysis and their aim therefore is to provide a single, off-the-shelf, objective source of data, analysis and market insight. Business Insights work in association with leading industry experts to produce a range of reports across a wide range of industry sectors.  By working in association with so many experts they are able to provide clients with more incisive market analysis specific to the client's industry sector. No other market analysis company provides such focused and trusted market analysis, across such a wide range of industry sectors.  View more research from Business Insights at http://www.fastmr.com/catalog/publishers.aspx?pubid=1003

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.